Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
Xiaohong Wang,Yonggang Liu,Zhiying Meng,Yun Wu,Shubin Wang,Gaowa Jin,Yingchun Qin,Fengyun Wang,Jing Wang,Haifei Zhou,Xiaoxing Su,Xiuhua Fu,Xiaolan Wang,Xiaoyu Shi,Zhenping Wen,Xiaoqiong Jia,Qiong Qin,Yongqiang Gao,Weidong Guo,Shun Lu
DOI: https://doi.org/10.21037/atm-20-7155
IF: 3.616
2021-04-01
Annals of Translational Medicine
Abstract:BACKGROUND: Activated epidermal growth factor receptor (<i>EGFR</i>) mutation is the main pathogenic cause of non-small cell lung cancer (NSCLC) in Asia. However, the impact of plasma <i>EGFR</i> mutation abundance, especially of the ultra-low abundance of <i>EGFR</i> mutation detected by highly sensitive techniques on clinical outcomes of first-line EGFR tyrosine kinase inhibitors (TKIs) for advanced NSCLC patients remains unclear.METHODS: We qualitatively detected baseline <i>EGFR</i> status of NSCLC tissues using amplification-refractory mutation system and quantified the plasma abundance of <i>EGFR</i> mutations through next-generation sequencing (NGS). Every 8-12 weeks, we performed dynamic detection of plasma mutation abundance and imaging evaluation. We analyzed the association between plasma abundance of <i>EGFR</i> sensitizing mutations, tumor size, tumor shrinkage percentage, concomitant <i>TP53</i> mutations, and clinical response to TKIs.RESULTS: This prospective study enrolled 135 patients with advanced NSCLC. The objective response rate (ORR) and disease control rate (DCR) for <i>EGFR</i> mutation-positive patients were 50.0% and 87.0%, respectively. When the cutoff value of plasma <i>EGFR</i> mutation abundance was 0.1%, the ORRs of TKI-treated patients were significantly different (60.0% for the >0.1% group <i>vs.</i> 21.4% for the ≤0.1% group, P=0.028). Median progression-free survival (PFS) was significantly longer for participants with a mutation abundance above 0.1% compared to those with a 0.01-0.1% abundance (log rank, P=0.0115). There was no significant association between plasma abundance of <i>EGFR</i> sensitizing mutations and tumor size, tumor shrinkage percentage, or concomitant <i>TP53</i> mutations. Cox multivariate analysis demonstrated that plasma mutation abundance was an independent predictive factor for PFS [hazard ratio (HR) 2.41, 95% confidence interval (CI): 1.12-5.20; P=0.025]. We identified 11 participants with the acquired T790M resistance mutation according to serial dynamic plasma samples.CONCLUSIONS: Liquid biopsy screening based on highly sensitive NGS is reliable for detecting drug resistance and actionable somatic mutations. The plasma abundance of the <i>EGFR</i> driver mutation affected clinical response to EGFR-TKIs in advanced NSCLC patients; prolongation of PFS was also observed in patients with an ultra-low abundance of <i>EGFR</i> sensitizing mutations.
oncology,medicine, research & experimental